Despite a poor prognosis and resistance to chemotherapy, new targeted therapies based on genetic mutations are improving outcomes for patients with biliary tract cancer.
Targeted Therapies in Biliary Tract Cancer
Zanidatamab, a bispecific HER2 antibody, shows promise in biliary tract cancer by requiring high HER2 expression and cross-linking receptors for efficacy.
Zanidatamab demonstrates an impressive 41% response rate and a 1-year duration of response in a large phase 2 BTC trial, offering a promising new option.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts NDA for Daraxonrasib in Metastatic Pancreatic Cancer
2
Teclistamab/Talquetamab Reduces Risk of Progression by 89% in R/R Multiple Myeloma
3
Advanced Renal Cell Carcinoma: Tailoring Second-Line Therapy After Prior Immunotherapy
4
Updated HARMONi Analysis Shows Consistent OS Benefit With Ivonescimab in EGFRm Lung Cancer
5